IHL 675a was originally being touted as a treatment for ARDS/SARDS which is the technical condition for the lung inflammation caused by covid (cytokine storm). Following pre-ind meeting with the FDA, IHL was advised to broaden the trial to include arthritis, IBD, and lung inflammation more broadly.
Could still be used to treat covid but I believe the market has significantly reduced due to effectiveness of preventative vaccines.